Healthcare CEO Accused of Diverting Cancer Research Funds to Strip Clubs
Finn's Take· TL;DR- CEO allegedly diverted $10.6M in cancer research funds toward personal luxury cars, debts, and strip club expenses instead of developing promised medical technology.
- Manipulated investor documents concealed collateral pledges and misrepresented cash restrictions, enabling continued fundraising while concealing previous fund misuse.
- SEC seeks permanent injunctions, penalties, and bars against defendants; case highlights vulnerabilities in private healthcare investment verification and due diligence.
The Alleged Scheme Unfolds
A Texas healthcare entrepreneur who promised investors revolutionary cancer treatment technology instead allegedly spent millions of their money on luxury cars, personal debts, and entertainment venues. The Securities and Exchange Commission charged Sumit Rai and three companies he controlled with misappropriating at least $10.6 million in investor funds between July 2020 and April 2023 .
Rai raised over $26 million from more than 180 investors between 2019 and 2023 by promoting what he called "cancer dialysis" technology designed to filter tumor cells from patients' blood . The companies told investors they were developing breakthrough medical devices for cancer treatment, prevention, and diagnosis.
The reality was starkly different. Rai allegedly used the funds to pay $2.3 million in personal credit card debt, cover $1 million in unrelated business associate debts, purchase $850,000 worth of luxury vehicles for an "elite social club" he attempted to start in Manhattan, and fund $5.1 million in cash withdrawals . The SEC complaint reveals that Rai spent about $85,000 of investor funds at a Texas strip club over just two days .
Deceptive Practices and Document Manipulation
The alleged scheme began in July 2020 when Rai obtained a personal line of credit using an SVN Med brokerage account—substantially funded by investor money—as collateral . To hide this arrangement, one institutional investor that put $315,000 into SVN Med received a brokerage statement with critical information deleted, specifically details revealing the account was pledged as collateral for Rai's personal loan .
Another institutional investor that committed $3 million received compliance certificates falsely representing millions as "unrestricted cash" when more than 92 percent was actually restricted . These manipulated documents allowed Rai to continue raising funds while concealing how previous investments were being used.
Massachusetts resident Kim deMora, who served as SVN Med's CEO from June 2019 to March 2022, was charged with aiding and abetting the alleged fraud . The SEC claims deMora signed loan authorization documents despite knowing Rai's ownership claims were false and later approved using investor funds to repay the loan without questioning how Rai spent the money .
Complex Corporate Shell Game
The case reveals a sophisticated web of corporate entities designed to obscure the flow of investor funds. Investors initially held convertible promissory notes issued by SVN Med and NVS Med, which were later consolidated under Onco Filtration through a series of assignments and conversions, then in September 2023, Rai induced investors to exchange those notes for nonconvertible promissory notes .
The complaint alleges Rai concealed the creation of a separate entity, Cancer Check, which obtained exclusive rights to sell Onco products without paying for them, generating approximately $1 million in revenue while providing no compensation to Onco or its investors . Payments due at the end of 2024 were allegedly unilaterally extended by Rai, and no payments have been made through at least August 2025 on notes valued at more than $210 million .
Implications for Healthcare Investment
This case highlights the vulnerabilities in private healthcare investment, where complex technology promises can mask fraudulent schemes. The alleged misuse of funds meant for cancer research represents not just financial fraud but a betrayal of investors who believed they were supporting potentially life-saving medical advances.
The SEC is seeking permanent injunctions, disgorgement with prejudgment interest, civil penalties, officer-and-director bars against Rai and deMora, and wants Rai barred from future securities offerings . Rai has disputed the allegations and said he will address them in court , while the case moves forward with the SEC requesting a jury trial.
For investors, this case underscores the critical importance of thorough due diligence, especially in emerging medical technology ventures where scientific complexity can obscure financial irregularities. The sophisticated document manipulation and corporate restructuring tactics alleged here demonstrate how fraudsters adapt traditional schemes to exploit the trust placed in healthcare innovation.